

49  
-44-

RECOMBINANT MVA VIRUS, AND THE USE THEREOF

ABSTRACT OF THE DISCLOSURE

The present invention relates to recombinant vaccinia  
viruses derived from the modified vaccinia virus Ankara  
5 (MVA) and containing and capable of expressing foreign  
genes which are inserted at the site of a naturally  
occurring deletion in the MVA genome, and the use of such  
recombinant MVA viruses for the production of polypeptides,  
e.g. antigens or therapeutic agents, or viral vectors for  
10 gene therapy, and the use of such recombinant MVA viruses  
encoding antigens as vaccines.

2025 RELEASE UNDER E.O. 14176